A phase I trial of OCR-002 for prevention of hepatic encephalopathy in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Ornithine phenylacetate (Primary) ; Glycerol phenylbutyrate
- Indications Hepatic encephalopathy
- Focus Adverse reactions; Pharmacokinetics
- 08 Jan 2016 Complete plasma data published in an Ocera Therapeutics media release.
- 16 Nov 2015 According to an Ocera Therapeutics media release, complete results from this trial will be submitted for presentation at an upcoming scientific conference.
- 16 Nov 2015 Results published in the Media Release